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required to recoup the intervention cost sooner. In this study, we focused on 
persons at high risks for both hypertension and diabetes and assessed the cost-
effectiveness of lifestyle interventions from a health plan perspective. 
METHODS: We used a Markov-based discrete event model to simulate the health 
and economic outcomes associated with lifestyle interventions compared with 
normal care over persons’ lifetime. The target population is U.S. adults with both 
prehypertension (a systolic blood pressure of 120-139 mm Hg or diastolic blood 
pressure of 80-89 mm Hg) and prediabetes. Data on the effect and costs of the 
intervention were obtained from published clinical trials. Outcomes included the 
incidences of diabetes and cardiovascular diseases, quality adjusted life years 
(QALY), and cost per QALY. Costs were expressed in 2012 US dollar. RESULTS: In 
persons aged 18-64, the intervention reduced the incidence of diabetes by 22% 
and major cardiovascular diseases by 7% over a lifetime. In persons aged 65-84, 
the corresponding reductions were 32% and 3% respectively. The intervention 
would save $3,500 and $1,500 per person among those aged 18-64 and 65-84 
respectively. The intervention achieved cost-even in 10 years among those aged 
18-64 and in 6 years among those aged 65-84 since initiation. CONCLUSIONS: 
Lifestyle intervention, targeting to persons at a high risk for both hypertension 
and diabetes, would lead to a greater lifetime saving and sooner recovery of the 
intervention costs, compared with targeting to those at risk for diabetes alone.  
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OBJECTIVES: Many children undergoing renal transplantation are vitamin D 
deficient, and hence, have an elevated risk of fracture, a costly event that can 
also reduce quality of life substantially. However, because testing a child’s 
vitamin D concentration is also costly, it makes sense to investigate whether 
universal vitamin D supplementation is more cost-effective than testing 
followed by supplementation for deficient patients only. The objective of this 
study was to determine the cost-effectiveness of (1) universal supplementation 
relative to (2) testing plus supplementation in patients with vitamin D deficiency 
and (3) neither testing nor supplementation. METHODS: A non-Markov decision 
model using Decision Maker (beta test version 2011.01.30b) was constructed to 
examine the three strategies: universal supplementation; testing with 
supplementation as needed; and no testing/supplementation. A time horizon of 
five years was assumed, and analysis was done from the health-system’s 
perspective. Probabilities, costs, and utilities were obtained from published 
literature and health-system. A 3% discount rate was applied to costs and results 
were reported in 2011 $US. Sensitivity and threshold analyses were conducted. 
RESULTS: The least costly strategy was universal supplementation which 
dominated no testing/ supplementation. The ICER for testing was 
$1,188,622/QALY compared with universal supplementation. The only parameter 
in the model that demonstrated sensitivity was the cost of testing. If it were 
reduced to $39.30 (from present cost of $102.11); then testing would become the 
dominant strategy. CONCLUSIONS: This study showed that universal vitamin D 
supplementation was a cost-effective strategy for reducing fractures among the 
pediatric renal transplant population. This strategy is further supported by the 
observation that supratherapeutic doses of vitamin D are rarely associated with 
toxicity and only at very extreme doses, although watching for toxicity would 
require adequate monitoring. The pleiotropic effects, i.e., decreased rejection of 
vitamin D supplementation may lower the cost per QALY and needs to be 
explored.  
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OBJECTIVES: To evaluate the cost effectiveness of ‘sore throat clinics’ (STCs) for 
prevention of acute rheumatic fever (ARF) in children in primary/intermediate 
schools. METHODS: A Markov model was developed to represent the lifetime 
impact of one year of primary prevention of ARF with STCs in high risk New 
Zealand (NZ) schools. It includes the incidence rate, natural history and costs of 
ARF and rheumatic heart disease; secondary prophylaxis; medical management 
of carditis; cardiac valve repair/replacement; the overall efficacy of community 
interventions to prevent rheumatic fever; and the annual cost per child of STCs. 
The model has a cycle of one year and terminates at age 95. It takes a health care 
payer perspective but excludes costs to families. Future costs and health benefits 
are discounted at 3.5% per annum. RESULTS: If STCs are 59% efficacious and cost 
on average NZ$135 per child per year, for schools at an incidence rate of 75 per 
100,000, STCs can be expected to cost about NZ$60,000 per QALY gained or 
NZ$190,000 per ARF case averted or NZ$2m per death averted. These figures are 
sensitive to the efficacy and annual cost of the intervention and the incidence of 
ARF but robust to uncertainty in other variables. The main costs are for project 
workers and laboratory culture and the main uncertainty is the efficacy of the 
intervention in NZ high risk schools. CONCLUSIONS: Sore throat clinics in high 
risk schools are likely to reduce the risk of acute rheumatic fever and thereby 
improve survival of Mâori and Pacific children, although they appear to be poorly 
cost effective from a NZ government perspective. Their cost effectiveness could 
be improved by containing staffing costs and/or reducing the cost of laboratory 
diagnosis of GAS. Implementation of this intervention would reduce the striking 
disparity between Mâori/Pacific and others.  
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OBJECTIVES: Delirium is common in hospitalised older patients and leads to 
poor long term outcomes. An ageing population means it is important to find 
cost-effective methods for both treatment and prevention. However, few 
economic evaluations of delirium interventions exist. This study generated an 
economic model to estimate the cost-effectiveness of an integrated, multi-
component targeted intervention (MTI) versus usual care for the prevention of 
delirium in elderly hospitalised patients. METHODS: A cohort Markov model 
was developed to calculate expected lifetime costs (health and social services 
perspective) and benefits (QALYs). Model face validity was checked with 
clinical experts and internal validity via secondary researchers. Health states 
were: dead, hospitalised, discharge location (home vs. institution). Utility 
values (SF-6D) were taken from a previous quality of life study. There was 
longer hospital stay, higher mortality rates and institutionalisation and lower 
utility values post delirium. Deterministic and probabilistic sensitivity 
analyses assessed uncertainty surrounding the incremental cost-effectiveness 
ratio (ICER). Value of information analysis was also conducted. RESULTS: With 
the MTI reducing delirium probability by one third, the deterministic ICER was 
just over £1000 per incremental QALY versus usual care. Probabilistic 
sensitivity analysis suggests there is 100% probability of cost-effectiveness 
when the QALY threshold is £30,000. At this threshold there is no expected 
value of perfect information (EVPI). Results were robust to one-way sensitivity 
analyses including changes in MTI effectiveness, delirium incidence and 
length of stay. CONCLUSIONS: The new decision model is a valid and useful 
tool for evaluating delirium interventions. In this analysis it indicates the MTI 
is highly cost-effective compared to usual care. Future research should focus 
on determining the impact of delirium on relative length of stay and on 
clarifying the utility values of elderly hospitalised patients with and without 
delirium.  
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OBJECTIVES: The number of patients with end-stage renal disease (ERSD) has 
rapidly increased globally. The incidence rate and prevalent rate on ERSD in 
Taiwan are in the first place of the world. While home haemodialysis (HHD) has 
been commonly used for ERSD patients in many countries, it has not been 
available in Taiwan. This study aims to assess the feasibility of HHD by 
conducting the cost-effectiveness analysis of different regimes of haemodialysis 
(hospital-based, satellite-based and home-based) from the perspectives of both 
patient and government. METHODS: A cost-effectiveness analysis was 
conducted based on a state transition Markov model for new ERSD patients with 
diabetes mellitus (DM) in Taiwan. Using published data from existing empirical 
studies, the incremental cost-effectiveness ratios (ICER) were calculated, and the 
cost-effectiveness acceptability curves (CEAC) were used to illustrate the results. 
Sensitivity analyses were implemented based on different costs of haemodialysis 
machines and transition rates. RESULTS: Satellite-based haemodialysis is the 
most economical choice in the initial stages of treatment. However, home 
haemodialysis becomes the most cost-effective after the twenty-third month 
(ICER=-US$126/utility), and becomes the most inexpensive choice after the third 
year. Compared with hospital-based and satellite-based haemodialysis, home 
haemodialysis saves about US$20,000 and US$13,500 in the end of the third year 
respectively, and US$55,000 and US$45,000 in the end of the fifth year 
respectively. Totally US$110 million was estimated to be saved in the end of 
third year once 10% of patients transfer from hospital-based haemodialysis to 
home haemodialysis in Taiwan. CONCLUSIONS: Given the better cost-
effectiveness of home haemodialysis, and its several advantages like more stable 
blood pressure, the elastic treatment time, privacy, and suitable for daily 
workers and disable patients compared with other haemodialyses, home 
haemodialysis is suggested to be the newly alternative choice for DM patients in 
Taiwan.  
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OBJECTIVES: To assess cost-utility of the prophylactic HPV vaccination on the 
prevention of ICC in brazilian amazonic region (State of Roraima). Invasive 
cervical cancer (ICC) remains an important public health problem, particularly in 
developing countries. The brazilian amazonic region is an high incidence area of 
ICC, comparable to low-income countries (crude incidence rate: 46/100.000), what 
suggests weaknesses in the current secondary prevention program. METHODS: 
A Markov model was developed as an analytic tool to simulate the natural 
history of HPV and its progress to ICC, considering the current preventive 
programs. Transition probabilities assumptions were based mainly on empirical 
data of local and national studies. The model evaluated the addition of the 
vaccine to 3 cervical cancer screening scenarios (0, 3 or 10 exams throughout 
life). RESULTS: The scenario of three Pap tests resulted in satisfactory calibration 
(base case). The addition of HPV vaccination would reduce by 35% the incidence 
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of ICC, in a setting of 70% vaccination coverage. The incremental ratio of cost-
effectiveness (IRCE) was R$ 1,200 for each year of quality-adjusted life (QALY) 
saved. The sensitivity analysis confirms the robustness of this result, and 
duration of immunity was the parameter with greater variation in. 
CONCLUSIONS: Vaccination has a favorable profile in terms of cost-utility, and 
its inclusion in the immunization schedule would result in substantial reduction 
in incidence and mortality of ICC in amazonic region of Brazil.  
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OBJECTIVES: The prevalence of Autism Spectrum Disorders (ASDs) has been 
increasing lately and treatment is expensive. Private insurers have historically 
provided lesser coverage for autism-related services than public insurers. This 
study compared the differences in health care expenditures and utilization 
between publicly and privately insured children with ASDs. METHODS: Data 
were from years 1997-2010 of the Medical Expenditure Panel Survey. 477 children 
with ASDs, of which 274 were privately insured and 184 had public insurance 
only, were identified. Expenditure measures (in 2010 dollars) included total 
health, home health and prescription expenditures and out-of-pocket 
expenditures on health and drugs. Utilization measures included the number of 
office-based visits, home health days and prescriptions. Generalized linear 
models, adjusted for sociodemographics and health status, were used to model 
utilization and expenditure to account for their skewness. STATA survey 
commands generated nationally representative estimates. RESULTS: Average 
total health care expenses were comparable for publicly and privately insured 
children with the latter having much higher out-of-pocket expenses ($1137.807 
vs $199.244). Publicly insured children used more prescriptions (13.52 vs 9.19) 
with lower out-of pocket expenses ($103.170 vs $206.964), and used more home 
health services (19.39 vs 7.67) with higher costs ($3,118.28 vs $782.43). After 
adjusting for sociodemographic differences and health status, no statistically 
significant differences in total health expenditures and utilization measures 
remained. However, publicly insured children spent 79% less (p < 0.000) and 63% 
less (p = 0.001) on average than privately insured children on out-of-pocket 
health and prescription expenditures respectively. CONCLUSIONS: Higher out-
of-pocket expenditures on health services and prescriptions for privately-insured 
children may be an indication of lower coverage for autism-related health 
services. State policies should correct this anomaly to reduce the burden on 
public insurers, as well as provide children with ASDs more options to get 
expensive treatment options covered.  
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OBJECTIVES: To determine the dose relativity of sevelamer hydrochloride (SH) 
and lanthanum carbonate (LC) monotherapy under real-world clinical conditions 
in the USA. METHODS: A post hoc analysis of an open-label, post-marketing study 
of patients (n = 2763) with end-stage renal disease (ESRD) in a real-world clinical 
setting in the USA. The analysis evaluated patients who converted from SH 
monotherapy at baseline to LC monotherapy for 16 weeks (12 week titration 
phase, 4 week maintenance period). Serum phosphate (P) levels and daily P 
binder dose were assessed at baseline and at weeks 12 and 16. RESULTS: A total 
of 953 patients were taking SH monotherapy at baseline; their mean SH dose  
was 7644±3660 mg/day and mean serum P level was 5.88±1.69 mg/dL. After  
16 weeks of LC monotherapy, mean LC dose was 2800±938 mg/day (SH:LC dose-
relativity 2.8) and mean P level was 5.93±1.85 mg/dL. In the subgroup of patients 
(n=191; 20%) receiving SH >7200 to ≤9600 mg/day (mean dose 9294±601 mg/day) 
at baseline, mean P level was 6.10±1.68 mg/dL. After LC treatment, their mean  
LC dose was 3018±800 mg/day (dose-relativity 3.1), and mean P level was 
6.42±1.88 mg/dL. Patients (n=192; 20%) receiving SH >9600 mg/day (mean dose 
13171±2388 mg/day) at baseline had a mean P level of 6.22±1.78 mg/dL. After LC 
treatment, their mean LC dose was 3156±808 mg/day (dose-relativity 4.2) and 
mean P level was 6.25±1.87 mg/dL. CONCLUSIONS: SH:LC dose relativity in the 
overall patient population was 2.8, in agreement with previous studies. However, 
the present study demonstrates that patients who require higher SH doses to 
maintain P control (>7200 mg/day; ~40% of patients) had higher SH:LC dose 
relativities (3.1–4.2). These findings have implications for the cost-effectiveness 
of P binder therapy in the treatment of patients with ESRD and 
hyperphosphatemia.  
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OBJECTIVES: To estimate annual productivity loss costs attributable to being 
overweight or obese in working adults with asthma patients in the US. 
METHODS: Working asthma patients (18-64 years old) were identified using the 
2003-2009 Medical Expenditure Panel Survey (MEPS). Asthma patients were 
identified by self-reported diagnosis, Clinical Classification Codes of 128, or ICD-
9-CM code of 493 and the identified patients were classified as normal-weight 
(18.5≤BMI<25), overweight (25≤BMI<30), and obese (BMI≥30). Productivity loss 
costs, which were measured based on missed work days due to illness or injury 
for one year and the hourly wage, were estimated using a two-part model to 
adjust for patients with zero costs. To estimate the productivity loss costs 
attributable to being overweight or obese, costs were estimated by assuming 
every patient is overweight or obese (i.e., treating the indicator variable as equal 
to 1) and re-estimating by assuming every patient is normal (i.e., treating the 
indicator variable as equal to 0). Then, the mean differences between the two 
estimated costs were considered the productivity loss costs attributable to 
overweight or obesity in asthma patients. All costs were converted to 2011  
US dollars using the Consumer Price Index. RESULTS: Annual average 
productivity loss costs attributable to obesity were $697(95%CI:$614-$780) per 
patient, 45% higher than overweight (at $480, 95%CI:$397-$563) and 92% higher 
than normal (at $363, 95%CI:$298-$428). The productivity loss costs in working 
asthma patients increased as patients were obese, older, or female. Also, the 
productivity loss costs attributable to overweight or obesity in working asthma 
patients were estimated at $89 (95%CI:$87-$91) or $250 (95%CI:$246-$254) per 
person per year, respectively. CONCLUSIONS: The productivity lost costs 
attributable to overweight and obesity in working US adults with asthma were 
substantial. To reduce the economic burden of treating asthma patients and 
enhance productivity, this study further highlights the importance of weight 
control.  
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OBJECTIVES: Polycystic kidney disease (PKD) is a genetic disorder affecting 
nearly 1 in 1000 Americans. Autosomal dominant PKD (ADPKD) occurs in both 
children and adults with symptoms often occurring in middle age. The objective 
of this retrospective study was to assess hospital-based utilization among 
patients with ADPKD. METHODS: A retrospective study of 1409 patients 
hospitalized in 2009 with a diagnosis of ADPKD in 71 hospitals continuously 
submitting over 36 months from the MedAssets health system database was 
conducted. Subsequent hospital visits were identified over a 24 month follow-up 
period. Age and gender as well as clinical complications, comorbidities and 
measures of utilization including number of visits and length of stay (LOS) were 
described. Multivariate regression was used to identify significant drivers of 
hospital-based utilization. RESULTS: The sample population had a mean age of 
50.6 years and was 51% male. Patients had an average of 17 outpatient and 2.5 
inpatient visits. Average LOS was 20.6 days, 45% were diagnosed with end stage 
renal disease (ESRD) and 24% received hemodialysis. Over 15.0% required a 
kidney transplant while 3.3% died in the hospital. Comorbidities included 
diabetes 21.9%, congestive heart failure (CHF) 12.6%, cardiopulmonary disease 
(CPD) 14.7%, cardiovascular disease (CVD) 11.3% and malignancy/tumor 12.3%. 
ESRD (1.3 visits, P<0.001), kidney transplant (2.0 visits, p<.0001), (1.4 visits, 
p<.0001), CPD (1.3 visits, p<.0001), CVD (1.4 visits, p<.0001), malignancy (1.3 visits, 
p<0.05) and previous myocardial infarction (1.3 visits, p<0.05) were associated 
with more visits. Similarly, ESRD (1.8 days, <.0001) and kidney transplant (1.5 
days, p=0.0005) were significantly associated with higher inpatient LOS. 
CONCLUSIONS: Patients with ADPKD consume a significant amount of health 
care resources, especially patients reaching the end stage of the disease. Further 
research is required to understand the effect of interventions/treatments on 
mitigating the progress of this disease.  
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OBJECTIVES: To assess patient emergency department (ED) waiting time, 
hospitalization rate immediately following ED visit, number of medications 
prescribed, and length of stay in ED among practices with various levels  
of electronic health record (EHR) functionality pertaining to mental illness-
related ED visits. METHODS: Data from 2006-2009 Centers for Disease Control 
and Prevention National Hospital Ambulatory Medical Care Survey ED files were 
used for this retrospective, cross-sectional study. Mental disorders were 
identified via: 1) International Classification of Diseases, Ninth Revision, Clinical 
Modification codes based on definitions by American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, and 2) mental 
health-related reason for visits as determined by the National Center for Health 
Statistics. EHR use among organizations was classified as no EHR, some EHR, 
basic EHR, and fully functional EHR based on the number and level of available 
features. Negative binomial regression models were applied using waiting time 
and visit length as outcome variables, while logistic and ordered logistic 
regression models were applied using hospitalization rate and number of 
medications prescribed as dependent variables, respectively. Regression 
analyses adjusted for patient demographics (age, gender, race/ethnicity, 
region/location, education, income, insurance status), level of triage and 
comorbidity, and hospital ownership status. To provide national estimates, all 
results were weighted and used standard errors calculated via Taylor-series 
approaches. RESULTS: Of the 24.3 million ED visits identified, 37.2%, 33.4%, and 
6.0% included some, basic, and fully functional EHRs, respectively. Having any 
sort of EHR was associated with 24% greater odds of hospitalization (p=0.032). 
